ストックスクリーナーアプリを入手
1.91
2.84%
-0.0558
アフターアワーズ：
1.91
Mei Pharma Inc (MEIP) 最新ニュース
MEI Pharma (NASDAQ:MEIP) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
MEI Pharma stock hits 52-week low at $1.83 amid market challenges - Investing.com
MEI Pharma stock hits 52-week low at $1.83 amid market challenges By Investing.com - Investing.com South Africa
MEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.com - Defense World
MEI PHARMA INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Follicular Lymphoma Market to Reach New Heights in Growth - openPR.com
Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron - Barchart.com
Virtu Financial LLC Purchases Shares of 10,744 MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com - The AM Reporter
StockNews.com Begins Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
MEI Pharma stock hits 52-week low at $2.27 amid market challenges - Investing.com Australia
MEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.28 amid market challenges - Investing.com Australia
MEI Pharma stock hits 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa
MEI Pharma, Inc. to Host Earnings Call - ACCESS Newswire
10 Cheap Chinese Stocks to Buy Now - Insider Monkey
11 Best Undervalued Stocks to Invest in Now - Insider Monkey
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - The Malaysian Reserve
C-COM Antenna Receives Eutelsat Type Approval - The Globe and Mail
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Alarm.com (ALRM) Q4 Earnings: What To Expect - The Globe and Mail
Why Tight Corporate-U.S. Treasury Yield Spreads Signal Good News for Ag Markets Prices - The Globe and Mail
MEI Pharma Reports Increased Losses Amid Strategic Shift - TipRanks
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position - BioSpace
MEI Pharma Inc. (MEIP) reports earnings - Quartz
MEI Pharma, Inc. SEC 10-Q Report - TradingView
Geriatric Population And Unmet Healthcare Needs Fuel Growth In Acute Myeloid Leukemia Market: A Key Driver ... - WhaTech
Malt Lymphoma Pipeline 2024: Detailed Clinical Trials - openPR
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.60 Average Target Price from Analysts - Defense World
No Headlines, No Problem: Why Technical Analysis Still Moves Stocks - The Globe and Mail
Layoff Tracker: Viracta, X4 and BMS Detail Current, Upcoming Cuts - BioSpace
Protein Bar Launch in Convenience Channel, Sending Shares of this MicroCap Higher - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.com - Defense World
3 Easy Ways to Build Up Your Portfolio in 2025 - The Globe and Mail
Scientist pleads guilty to stealing trade secrets for Chinese pharma company - Fox28 Savannah
Kimberly-Clark: A Regal Opportunity in This Dividend King - The Globe and Mail
ROSEN, A LEADING LAW FIRM, Encourages Infinity Pharmaceuticals, - GuruFocus.com
Will PepsiCo Hike Its Dividend Soon?Looks LikelyValue Investors Love the Stock - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com - Defense World
Assenagon Asset Management S.A. Buys 2,285 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
B-cell Non-hodgkin Lymphoma Clinical and Non-Clinical - openPR
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):